Pannysylvania Magazine

DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Market Insights, Epidemiology, and Market Forecast – 2036.” This comprehensive report provides an in-depth understanding of Relapsed/Refractory Acute Myeloid Leukemia, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Key Takeaways from the Relapsed/Refractory Acute Myeloid Leukemia Market

• The Relapsed/Refractory Acute Myeloid Leukemia market in the leading markets is expected to grow significantly by 2036.

• DelveInsight estimates that the R/R AML market across the 7MM is projected to increase from approximately USD 10 billion in 2022 to nearly USD 16 billion by 2036.

• According to the American Cancer Society, approximately 22,720 people are expected to be diagnosed with AML in the United States in 2026, while nearly 11,500 deaths are anticipated.

• DelveInsight estimates that the United States accounted for nearly 22,000 incident AML cases in 2025, representing the largest patient population among the 7MM.

• Germany is projected to experience a 14.6% increase in newly diagnosed AML cases by 2050, reflecting the impact of an aging population.

• AML incidence in Japan continues to rise with age, reaching 10–17 cases per 100,000 individuals over 69 years, compared with 0.6–6.0 per 100,000 among younger populations.

• FDA-approved targeted therapies including REVUFORJ, REZLIDHIA, XOSPATA, MYLOTARG, and TIBSOVO continue to reshape the treatment landscape for genetically defined AML subtypes.

• Leading companies including Syndax Pharmaceuticals, Astellas Pharma, Rigel Pharmaceuticals, Dr. Reddy’s Laboratories, Ryvu Therapeutics, SELLAS Life Sciences, Ipsen, and others are actively developing innovative therapies expected to transform R/R AML treatment.

• Promising pipeline therapies include RVU120, Galinpepimut-S (GPS), IPN60340, SLS009, and others.

Keen to know more about the market? Request our sample page athttps://www.delveinsight.com/sample-request/relapsed-refractory-acute-myeloid-leukemia-market

Key Factors Driving the Relapsed/Refractory Acute Myeloid Leukemia Market

Increasing Incidence of Acute Myeloid Leukemia

The growing global burden of AML, particularly among elderly populations, continues to increase the number of patients progressing to relapsed or refractory disease, thereby driving demand for innovative treatment options.

Expansion of Precision Medicine

Improved understanding of AML genetics has accelerated the adoption of mutation-specific therapies targeting FLT3, IDH1, IDH2, NPM1, and KMT2A, enabling personalized treatment strategies with improved clinical outcomes.

Growing Adoption of Menin Inhibitors and Targeted Therapies

The approval of REVUFORJ, the first FDA-approved menin inhibitor, has opened a new era in AML treatment. Continued development of targeted agents and immunotherapies is expected to significantly improve outcomes for patients with relapsed or refractory disease.

Robust Clinical Pipeline

A strong late-stage pipeline comprising menin inhibitors, CDK8/19 inhibitors, WT1-targeted immunotherapies, γδ T-cell activating antibodies, and combination regimens is expected to transform the future treatment paradigm for R/R AML.

Relapsed/Refractory Acute Myeloid Leukemia Competitive Landscape

Current treatment options for R/R AML include chemotherapy, stem cell transplantation, targeted therapies, hypomethylating agents, radiotherapy, leukapheresis, and supportive care. FDA-approved targeted therapies such as REVUFORJ, REZLIDHIA, XOSPATA, MYLOTARG, and TIBSOVO continue to expand treatment options for genetically defined patient populations.

Several Relapsed/Refractory Acute Myeloid Leukemia therapies in development include:

• RVU120 (Ryvu Therapeutics)

• Galinpepimut-S (SELLAS Life Sciences)

• IPN60340 (Ipsen)

• SLS009 (SELLAS Life Sciences)

• and others.

These investigational therapies target multiple mechanisms including CDK8/19 inhibition, WT1-directed immunotherapy, BTN3A-mediated γδ T-cell activation, and other immune-based approaches designed to overcome resistance, improve remission rates, and prolong survival in patients with relapsed or refractory AML.

Discover more about therapies set to grab major Relapsed/Refractory Acute Myeloid Leukemia market share @ Relapsed/Refractory Acute Myeloid Leukemia Treatment Landscape

Recent Developments in the Relapsed/Refractory Acute Myeloid Leukemia Market

• In January 2026, Ipsen announced that the US FDA granted Breakthrough Therapy Designation (BTD) to IPN60340 in combination with venetoclax and azacitidine for first-line unfit AML.

• In January 2026, Ryvu Therapeutics announced positive feedback from the US FDA regarding expansion of the RVU120 (romaciclib) clinical development program in combination with venetoclax for R/R AML.

• In December 2025, SELLAS Life Sciences announced progress in the ongoing Phase III REGAL trial evaluating Galinpepimut-S (GPS) as maintenance therapy following second complete remission in AML patients.

• In November 2025, the US FDA approved ziftomenib (KOMZIFTI) for adults with relapsed/refractory AML harboring susceptible NPM1 mutations who have no satisfactory alternative treatment options.

• In October 2025, the US FDA approved REVUFORJ (revumenib) for patients with R/R AML harboring susceptible NPM1 mutations, expanding the indication for the first-in-class menin inhibitor.

What is Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)?

Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) is an aggressive hematologic malignancy characterized by the recurrence of leukemia after achieving remission (relapsed AML) or failure to respond to initial induction therapy (refractory AML). AML originates in the bone marrow and results in the uncontrolled proliferation of immature myeloid cells, leading to impaired normal blood cell production. Treatment options depend on patient age, genetic mutations, fitness, and previous therapies, and may include intensive chemotherapy, stem cell transplantation, targeted therapies, hypomethylating agents, immunotherapies, and supportive care. Despite recent therapeutic advances, R/R AML remains associated with poor prognosis and significant unmet medical need, driving the development of novel precision medicines and immunotherapeutic approaches.

Relapsed/Refractory Acute Myeloid Leukemia Epidemiology Segmentation

The Relapsed/Refractory Acute Myeloid Leukemia epidemiology section provides insights into the historical and current AML patient pool and forecasted trends across the leading markets. The R/R AML market report provides epidemiological analysis for the study period 2022–2036, segmented into:

• Total Incident Cases of Acute Myeloid Leukemia (AML)

• Gender-specific Incident Cases of AML

• Age-specific Incident Cases of AML

• Genetic Mutation-specific Incident Cases of AML (NPM1, FLT3, IDH1, and IDH2)

• Total Treated Cases of AML

• First-line Fit (Eligible for Induction) Cases

• First-line Unfit (Ineligible for Induction) Cases

• Relapsed/Refractory Acute Myeloid Leukemia Cases

Scope of the Relapsed/Refractory Acute Myeloid Leukemia Market Report

• Therapeutic Assessment: Relapsed/Refractory Acute Myeloid Leukemia current marketed and emerging therapies

• Relapsed/Refractory Acute Myeloid Leukemia Market Dynamics: Key Market Forecast Assumptions of Emerging R/R AML Drugs and Market Outlook

• Key Companies: Syndax Pharmaceuticals, Astellas Pharma, Rigel Pharmaceuticals, Dr. Reddy’s Laboratories, Ryvu Therapeutics, SELLAS Life Sciences, Ipsen, and others

• Key Therapies: REVUFORJ (Revumenib), REZLIDHIA (Olutasidenib), XOSPATA (Gilteritinib), MYLOTARG (Gemtuzumab Ozogamicin), TIBSOVO (Ivosidenib), RVU120, Galinpepimut-S (GPS), IPN60340, SLS009, and others

• Competitive Intelligence Analysis: SWOT Analysis and Market Entry Strategies

• Unmet Needs, KOL’s Views, Analyst’s Views, Relapsed/Refractory Acute Myeloid Leukemia Market Access and Reimbursement

To know more about Relapsed/Refractory Acute Myeloid Leukemia companies working in the treatment market, visit @ Relapsed/Refractory Acute Myeloid Leukemia Clinical Trials and Therapeutic Assessment

Table of Contents

• Relapsed/Refractory Acute Myeloid Leukemia Market Report Introduction

• Executive Summary for Relapsed/Refractory Acute Myeloid Leukemia

• Key Events

• AML Epidemiology and Market Forecast Methodology

• Relapsed/Refractory Acute Myeloid Leukemia Market Overview at a Glance

• Disease Background and Overview

• Treatment and Management

• Epidemiology and Patient Population

• Patient Journey

• Marketed Therapies

• Emerging Therapies

• Relapsed/Refractory Acute Myeloid Leukemia 7MM Market Analysis

• Country-wise Market Analysis (2022–2036)

• Unmet Needs

• SWOT Analysis

• KOL Views

• Market Access and Reimbursement

• Appendix

• Report Methodology

• DelveInsight Capabilities

• Disclaimer

• About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through its subscription-based platform, PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/